New hepatitis b pill shows promise in early human trial

NCT ID NCT04536337

Completed Disease control Sponsor: Aligos Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an experimental oral drug called ALG-000184 in healthy volunteers and people with chronic hepatitis B. The main goals are to check safety, how the body processes the drug, and whether it can lower hepatitis B virus levels. Participants take the drug daily for up to 12 weeks, sometimes combined with a standard treatment. Results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALG-000184 (an experimental oral drug)
What this could lead to: If successful, this could point toward a new treatment option for chronic hepatitis B, potentially reducing virus levels and improving disease control.
What could go wrong: This is an early Phase 1 trial focused on safety, so it's too soon to know if ALG-000184 will work. The drug may cause side effects or fail to reduce the virus effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Locations

ACS

Auckland, New Zealand
CAP Research

Quatre Bornes, Mauritius, 72218, Mauritius
Nanfang Hospital of Southern Medical University

Guangzhou, Guangdong, China
PMSI Republican Clinical Hospital "T. Mosneaga", ARENSIA Exploratory Medicine Phase I Unit

Chisinau, Moldova
Prince of Wales

Shatin, Hong Kong
Queen Mary Hospital

Hong Kong, Hong Kong
Saint Vincent's Hospital Melbourne

Fitzroy, Victoria, 3065, Australia
The First Hospital of Jilin University

Changchun, Jilin, 130021, China
The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400016, China
Western Health

Footscray, Victoria, 3011, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.